A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
| 1811 | Th1202 | Pembrolizumab | Heavy Chain Sequence Full view | 711 | IIIc | Cancer | Keytruda | Merck Sharp & Dohme Corp. | Lyophilized Powder | Intravenous infusion | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1815 | Th1206 | Nivolumab | Heavy Chain Sequence Full view | 710 | IIIc | Cancer | Opdivo | E.R. Squibb & Sons, L.L.C. | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1821 | Th1212 | Insulin Pork | A chain GIVEQCCTSICS Full view | 68 | Ia | Metabolic Disorders | Iletin II | Lilly | sterile suspension | Subcutaneous | Hypoglycemic Agents, Antidiabetic Agents | Insulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |
| 1829 | Th1219 | Anti-thymocyte Globulin (Rabbit) | NA Full view | 0 | IIIb | Immunological Disorders | ATG-Fresenius | Genzyme Inc. | Concentrate for solution for infusion. | Intravenous | Antibody | T-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3 |